UK NHS trusts denying patients expensive drugs via 'red lists'

14 April 2011

In a bid to cut budgets, National Health Service (NHS) managers in the UK are preventing family doctors from prescribing drugs for conditions such as diabetes, heart disease, Parkinson’s disease and osteoporosis, adding the medicines to so-called "red lists," which means they can only be prescribed by a hospital consultant and not a General Practitioner.

It also means that many patients find it more difficult to obtain the most effective drugs free on the NHS, even though they have been approved by the medicines rationing watchdog the National Institute for Health and Clinical Excellence (NICE).

Patients' groups described the disclosure as "outrageous" and "extremely worrying," reports the Daily Telegraph newspaper, noting that one health authority has added 32 drugs to its red list in the past year, while another said it intended to fine doctors who wrote letters requesting that such medicines be prescribed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical